Endometriosis Market to Reach USD 2.04 Bn to 2025, Says GlobalData in Its In-demand Report Available at MarketPublishers.com15 Feb 2017 • by Natalie Aster
LONDON – The prevalence rate of endometriosis, including confirmed and suspected cases, is projected to increase from 9.6 million to 11.3 million globally through to 2025.
The endometriosis market dynamics is not expected to change radically over the next decade with respect to the existing and future players in the endometriosis marketplace. AbbVie and Bayer are expected to keep on having a significant presence, as they are adopting different strategies to introduce novel therapeutics to the market. Other firms with novel chemical entities may also come near to surface by 2015-end.
The endometriosis market is set to see moderate growth to reach USD 2.04 billion through to 2025. Such moderate market growth will likely be fuelled mainly by the surging number of diagnosed endometriosis patients across the 7MM and the highly expected introduction of the new gonadotrophin-releasing hormone (GnRH) antagonist, elagolix, anticipated to be released by 2018. Meanwhile, patent expirations of several branded drug products and the poorly populated endometriosis pipeline are expected to limit the market growth in the offing.
Present-day endometriosis therapies approved by FDA encompass analogues of GnRH, danazol, and progestins. Off-label medical therapy for endometriosis, typically prescribed before definitive diagnosis is established, comprises hormonal contraceptives and NSAIDs.
In-demand report “OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025” created by GlobalData’s examines the market on a global level with a focus on key countries. The study gives a detailed overview of the disease; presents annualised market revenue, annual cost of therapy and therapy usage pattern data, historical and forecast. The report identifies and describes unmet needs, maps clinical trials and implications for the market. It examines key trends, innovative technologies and products, market segments, etc. A comprehensive pipeline analysis is included, with a special focus on drugs in late-stage development. The research examines the competitive scene and casts light on the performance of different competitors. It offers data on drug sales in the worldwide market for endometriosis therapeutics during 2013-2023. The report also gives an insightful analysis of the major industry restraints, drivers, and challenges.
Other in-demand studies by this publisher can be found at GlobalData page at MarketPublishers.com.